NEWS

3 december 2019
3 december 2019

Xenikos presents promising new data from expanded access program (EAP) using T-Guard® to treat steroid-refractory acute GVHD at ASH Annual Meeting

Do you like it?
Read more
2 december 2019
2 december 2019

Xenikos appoints Stanley Musial as Chief Financial Officer and Chief Business Officer

Do you like it?
Read more
14 oktober 2019
14 oktober 2019

Xenikos receives FDA Fast Track designation for T-Guard® for treating steroid-refractory acute graft-versus-host disease

Do you like it?
Read more
Load more